edoxaban


Also found in: Medical, Wikipedia.
Translations

edoxaban

n edoxabán m
References in periodicals archive ?
14 December 2011 - Daiichi Sankyo Company (TYO:4568) said on Tuesday that results of a recent analysis showed that edoxaban, a direct oral once-daily factor Xa inhibitor, significantly reduced the risk of developing venous thromboembolism (VTE) in patients who have undergone total knee or hip arthroplasty when compared to enoxaparin.
The agency also asked for additional data to support inclusion of edoxaban and enoxaparin in the label, and indicated it needs to finalize its review of the clinical amendments to Portolas post-marketing commitments that recently were submitted.
This announcement follows the first marketing approval for edoxaban 15 mg and 30 mg tablets by the Japanese Ministry of Health, Labour and Welfare in April 2011 and marks the first time edoxaban is commercially available to patients in any global market.
Portola is currently evaluating andexanet alfa in this global, Phase 3b/4 single-arm, open-label study in patients receiving apixaban, rivaroxaban, edoxaban or enoxaparin who present with an acute major bleed.
26 April 2011 - Japanese Daiichi Sankyo Company Limited (TYO: 4568) said last Friday it has obtained its first marketing approval for LIXIANA (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 mg tablets, from Japan's Ministry of Health, Labor and Welfare (MHLW).
They will compare clinical outcomes for warfarin, the old standby anticoagulant, with four newer drugs apixaban, dabigatran, edoxaban, and rivaroxaban.
4 February 2010 - Japanese Daiichi Sankyo Company Limited (TYO: 4568) said yesterday it has started a pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor, for the treatment and prevention of recurrent venous thromboembolism.
Limited today announced that it has entered into an agreement with Servier Canada (Laval, Quebec) whereby Servier Canada will market the oral, once-daily anti-coagulant edoxaban in Canada, if approved by the Canadian health authority.
3 February 2010 - Japan-based pharmaceutical company Daiichi Sankyo Company Limited (TYO: 4568) announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor.
Portola Pharmaceuticals has announced that it has entered into a clinical partnership deal with Daiichi Sankyo for the development of andexanet alfa as an antidote for edoxaban, Daiichi Sankyos Factor Xa inhibitor, in Japan.
DSE currently has no affiliated companies in these countries, so this agreement will contribute significantly to the growth of edoxaban in Europe.
3 oral Factor Xa inhibitors are presently on the market in Japan, Bristol-Myers Squibb and Pfizers apixaban, Bayer HealthCares rivaroxaban, and Daiichi Sankyos edoxaban but an antidote is still not sanctioned .